Ting-Ting Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ting-Ting Zhao has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
- Bo Guo
Department of Cell Biology and Genetics, School of Basic Medical Sciences, Xi’an Jiaotong University Health Science Center
1 shared publication - Fei Han
Department of Obstetrics and Gynecology, Women and Children's Hospital of Chongqing Medical University, Chongqing 401147, China; Department of Health Toxicology, School of Public Health, Chongqing Medical University, Chongqing 400016, China
1 shared publication - Fei Yang
Department of Neurology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, China
1 shared publication - Gui-Lian Xu
Department of Immunology, Army Medical University, Chongqing, China
1 shared publication - Ke-Qin Zhang
National Engineering Laboratory for Modern Silk, College of Textile and Clothing Engineering, Soochow University, Suzhou
1 shared publication - Man Jiang
Department of Physiology, School of Basic Medicine and Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
1 shared publication
Latest Publications
- Open Access
- 9 September 2026
- Published by Wiley in Advanced Science
- p. e77690
SOX30 Facilitates Triple‐Negative Breast Cancer Metastasis via TNFR2–NF‐κB Signaling and Tumor Microenvironment Remodeling
Triple‐negative breast cancer (TNBC) remains therapeutically challenging due to its aggressive metastatic potential, high recurrence rates, and lack of effective targeted therapies. Herein, we identified that SOX30 is significantly upregulated in TNBC and correlates with poor clinical prognosis. Functionally, SOX30 specifically drives TNBC metastasis and activates the TNFR2‐mediated downstream NF‐κB signaling cascade. Mass cytometry profiling of the tumor immune microenvironment revealed that SOX30 facilitates the recruitment of tumor‐associated macrophages (TAMs) within pulmonary metastases, a finding corroborated by flow cytometric quantification. Mechanistically, downstream pathway analyses identified that SOX30 induces activation of the TNFR2–NF‐κB axis and concurrently upregulates expression of the chemokine CCL20. Therapeutic intervention with CCL20 neutralizing antibodies or small‐molecule CCR6 inhibitors effectively attenuated metastatic progression and abrogated TAM infiltration. Strikingly, combinatorial blockade using the TNFR2 inhibitor etanercept together with a CCR6 inhibitor exhibited superior anti‐metastatic efficacy relative to control treatments. Collectively, our findings delineate a novel oncogenic SOX30–TNFR2–NF‐κB–CCL20/CCR6 axis driving TNBC metastasis. These results establish SOX30 as a promising prognostic biomarker and a potential therapeutic target for anti‐metastatic strategies in TNBC.
- 9 September 2026
- Published by Wiley in Advanced Science
- p. e77690
Open AccessSOX30 Facilitates Triple‐Negative Breast Cancer Metastasis via TNFR2–NF‐κB Signaling and Tumor Microenvironment Remodeling
Triple‐negative breast cancer (TNBC) remains therapeutically challenging due to its aggressive metastatic potential, high recurrence rates, and lack of effective targeted therapies. Herein, we identified that SOX30 is significantly upregulated in TNBC and correlates with poor clinical prognosis. Functionally, SOX30 specifically drives TNBC metastasis and activates the TNFR2‐mediated downstream NF‐κB signaling cascade. Mass cytometry profiling of the tumor immune microenvironment revealed that SOX30 facilitates the recruitment of tumor‐associated macrophages (TAMs) within pulmonary metastases, a finding corroborated by flow cytometric quantification. Mechanistically, downstream pathway analyses identified that SOX30 induces activation of the TNFR2–NF‐κB axis and concurrently upregulates expression of the chemokine CCL20. Therapeutic intervention with CCL20 neutralizing antibodies or small‐molecule CCR6 inhibitors effectively attenuated metastatic progression and abrogated TAM infiltration. Strikingly, combinatorial blockade using the TNFR2 inhibitor etanercept together with a CCR6 inhibitor exhibited superior anti‐metastatic efficacy relative to control treatments. Collectively, our findings delineate a novel oncogenic SOX30–TNFR2–NF‐κB–CCL20/CCR6 axis driving TNBC metastasis. These results establish SOX30 as a promising prognostic biomarker and a potential therapeutic target for anti‐metastatic strategies in TNBC.